Experimental CAR-T therapy targets tough autoimmune blood diseases

NCT ID NCT07441525

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called RD06-05, a type of CAR-T cell therapy, in 27 adults with autoimmune blood diseases like immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), or Evans syndrome. The therapy aims to control the disease by targeting and reducing harmful immune cells. Participants receive one of two dose levels, and the study monitors safety, side effects, and how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune thrombocytopenic purpura Evans syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEMOLYTIC ANEMIA EVANS SYNDROME PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••